

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

EVERGREEN THERAGNOSTICS, INC.

Petitioner

– vs. –

ADVANCED ACCELERATOR APPLICATIONS SA

Patent Owner

---

CASE NO. PGR2021-00002

**DECLARATION OF STEPHAN MAUS  
UNDER 37 C.F.R. § 1.68  
IN SUPPORT OF PETITION FOR  
POST GRANT REVIEW OF U.S. PATENT NO. 10,596,278  
(ALL CLAIMS)**

## TABLE OF CONTENTS

I.	INTRODUCTION.....	1
II.	BACKGROUND AND QUALIFICATIONS .....	7
III.	PATENT LAW BACKGROUND .....	9
	A. Level of Ordinary Skill in the Art.....	10
	B. The Scope and Content of the Prior Art.....	11
	C. Differences Between the Prior Art and What Was Claimed.....	12
	D. Objective Evidence of Non-Obviousness .....	13
IV.	BACKGROUND OF THE TECHNOLOGY AS OF 2018.....	14
V.	THE '278 PATENT (EX. 1002) .....	26
VI.	THE LEVEL OF ORDINARY SKILL IN THE ART.....	34
VII.	CLAIM CONSTRUCTION .....	36
VIII.	DETAILED ANALYSIS .....	41
	A. Overview of the Prior Art.....	45
	B. Independent Claim 1 and Dependent Claims 8-17 and 19 of the '278 Patent Are Anticipated by the Maus Article (Ex. 1009).....	54
	C. Independent Claim 1 and Dependent Claims 8-17 and 19 of the '278 Patent Would Have Been Obvious Over the Maus Article (Ex. 1009) in View of Kwekkeboom (Ex. 1010).....	68
	D. Dependent Claims 2-4 Would Have Been Obvious Over the Maus Article (Ex. 1009) Alone or in View of Kwekkeboom (Ex. 1010) and General Knowledge that Ascorbic Acid and Sodium Ascorbate are Interchangeable as Radiolytic Stabilizers as Evidenced by Scott (Ex. 1015).....	86

Declaration of Stephan Maus Under 37 C.F.R. § 1.68 in Support of  
Petition for Post Grant Review of U.S. Patent No. 10,596,278

- E. Dependent Claim 15 Would Have Been Obvious Over the Maus Article (Ex. 1009) Alone or in View of Kwekkeboom (Ex. 1010), de Blois (Ex. 1017), and SEC Statement (Ex. 1018) .....91
- F. Dependent Claim 18 Would Have Been Obvious Over the Maus Article (Ex. 1009) Alone or in View of Kwekkeboom (Ex. 1010) and General Knowledge that the Volume of the Pharmaceutical Aqueous Solution Can Vary.....94
- G. Dependent Claims 5-7 Would Have Been Obvious Over the Maus Article (Ex. 1009) Alone or in View of Kwekkeboom (Ex. 1010), General Knowledge that Ascorbic Acid and Sodium Ascorbate are Interchangeable as Radiolytic Stabilizers as Evidenced by Scott (Ex. 1015), and De León-Rodríguez (Ex. 1014) and/or Other Prior Art Disclosing That it Was Routine to Maintain pH with an Acetic Acid/Sodium Acetate Buffer During Complexation.....96
- H. Dependent Claims 5-7 Would Have Been Obvious Over the Maus Article (Ex. 1009) Alone or in View of Kwekkeboom (Ex. 1010), the '536 Patent (Ex. 1013), General Knowledge that Ascorbic Acid and Sodium Ascorbate are Interchangeable as Radiolytic Stabilizers as Evidenced by Scott (Ex. 1015), and De León-Rodríguez (Ex. 1014) and/or Other Prior Art Disclosing That it Was Routine to Maintain pH with an Acetic Acid/Sodium Acetate Buffer During Complexation ..... 106
- I. Independent Claim 20 Would Have Been Obvious Over the Maus Article (Ex. 1009) Alone or in View of Kwekkeboom (Ex. 1010), General Knowledge that Ascorbic Acid and Sodium Ascorbate are Interchangeable as Radiolytic Stabilizers as Evidenced by Scott (Ex. 1015), and De León-Rodríguez (Ex. 1014) and/or Other Prior Art Disclosing That it Was Routine to Maintain pH with an Acetic Acid/Sodium Acetate Buffer During Complexation..... 119
- J. Independent Claim 20 Would Have Been Obvious Over the Maus Article (Ex. 1009) Alone or in View of Kwekkeboom (Ex. 1010), the '536 Patent (Ex. 1013), General Knowledge that Ascorbic Acid and Sodium Ascorbate are Interchangeable as Radiolytic Stabilizers as Evidenced by Scott (Ex. 1015), and De León-Rodríguez (Ex. 1014) and/or Other Prior Art Disclosing That it

Declaration of Stephan Maus Under 37 C.F.R. § 1.68 in Support of  
Petition for Post Grant Review of U.S. Patent No. 10,596,278

Was Routine to Maintain pH with an Acetic Acid/Sodium Acetate  
Buffer During Complexation .....131

K. Dependent Claims 21-25 Would Have Been Obvious Over the  
Maus Article (Ex. 1009) Alone or in View of Kwekkeboom (Ex.  
1010), Optionally in View of the '536 Patent (Ex. 1013), General  
Knowledge that Ascorbic Acid and Sodium Ascorbate are  
Interchangeable as Radiolytic Stabilizers as Evidenced by Scott  
(Ex. 1015), and De León-Rodríguez (Ex. 1014) and/or Other Prior  
Art Disclosing That it Was Routine to Maintain pH with an Acetic  
Acid/Sodium Acetate Buffer During Complexation.....143

L. If the Process Limitations Are Considered, Claims 8 and 11-14  
Would Have Been Obvious Over the Maus Article (Ex. 1009) in  
View of the '536 Patent (Ex. 1013) or Obvious Over the Maus  
Article (Ex. 1009) in View of Kwekkeboom (Ex. 1010) and the  
'536 Patent (Ex. 1013) .....152

M. If the Process Limitations Are Considered, Claims 9 and 10  
Would Have Been Obvious Over the Maus Article (Ex. 1009) in  
View of the '536 Patent (Ex. 1013) and General Knowledge that  
Ascorbic Acid and Sodium Ascorbate are Interchangeable as  
Radiolytic Stabilizers as Evidenced by Scott (Ex. 1015) or  
Obvious Over the Maus Article (Ex. 1009) in View of  
Kwekkeboom (Ex. 1010), the '536 Patent (Ex. 1013), and General  
Knowledge that Ascorbic Acid and Sodium Ascorbate are  
Interchangeable as Radiolytic Stabilizers as Evidenced by Scott  
(Ex. 1015).....167

N. If the Process Limitations Are Considered, Claim 17 Would Have  
Been Obvious Over the Maus Article (Ex. 1009) Alone or in View  
of Kwekkeboom (Ex. 1010) and General Knowledge That Batch  
Size Can Vary as Evidenced by Luna-Gutierrez (Ex. 1025) .....170

O. The Claims of the '278 Patent Are Not Enabled if the Recited  
Stability Limitations Are Not an Inherent Property of the  
Pharmaceutical Aqueous Solutions Taught in the Prior Art .....172

P. Claim 24 of the '278 Patent is Invalid for Improper Dependency...176

...

Declaration of Stephan Maus Under 37 C.F.R. § 1.68 in Support of  
Petition for Post Grant Review of U.S. Patent No. 10,596,278

IX. CONCLUSION .....177

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.